Pharmaceutical Distribution Business — Business Valuation Multiple
EBITDA Valuation Guide · Small & Mid-Sized Businesses
Actual EBITDA multiples can vary materially based on EBITDA size, growth, recurring revenue, margins, customer concentration, owner dependence, geography and other company-specific factors.
Min
3.5×
Typical
5×
Max
6.5×
Revenue Model
Recurring
Capital Intensity
Medium
A typical multiple of 5× EBITDA reflects mid-market transactions in the $1–$50M revenue range.
Overview
Pharmaceutical distribution businesses typically trade at 3.5×–6.5× EBITDA. Regulatory wholesaler licensing, healthcare system framework supply agreements, and cold chain and specialist logistics capability create significant barriers to entry. Manufacturer preferred distributor agreements provide revenue predictability. Drug pricing and reimbursement risk and supply chain disruption on critical medicines are the primary risk factors.
Key Value Drivers
- Regulatory licensed wholesaler status
- Healthcare system framework supply agreements
- Cold chain and specialist logistics capability
- Manufacturer preferred distributor agreements
- Regulatory barriers to entry
Key Risks
- Healthcare procurement reform
- Drug pricing and reimbursement risk
- Regulatory compliance and audit
- Supply chain disruption on critical medicines
- Margin pressure from central procurement
Related Industries
Disclaimer: All multiples are indicative estimates only and are not formal valuations or investment advice. They should not be relied upon for financial decision-making without independent professional advice.